Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
Sign In

People

Language:
EN FR

Contact details

Allen & Overy LLP
52 avenue Hoche
Paris
75008
France

Telephone icon+33 (0)1 40 06 50 33
Send email

Download contact detailsDownload contact details View officeView office

  Laetitia Benard

Partner

Paris

Laëtitia leads the Paris Intellectual Property practice and is co-head of Allen & Overy's Life Sciences Group worldwide. Laëtitia is a litigator specializing in domestic and cross-border patent litigation.
She has a wealth of expertise in all intellectual property areas, more particularly having acted in numerous complex patent disputes involving pharmaceutical and high tech companies. She also advises on patent portfolios, patent validity, and freedom to operate issues. She has specific knowledge of the life sciences field, in which she also advises on various regulatory and contractual matters such as price regulation, advertisement for medicines, transfers of technology and anti-bribery rules.
Laëtitia frequently publishes on life sciences regulatory topics and has written a number of clients alerts on issues such as biosimilars, the-EFPIA-Transparency-Initiative, and the online sale of medicines. Her publications include "Interim injunctions over patents – The French practice" in Managing Intellectual Property (February 2013); "Overview of Life Sciences law in France" in Chambers Life Sciences Guide 2013; "Why France is a good forum for preliminary injunctions in patent matters" in Global Business Magazine, 2012; "Supplementary Protection Certificates – CJEU provides welcome clarifications" International Who's Who Legal - Life Sciences, 2012; "Preliminary injunctions in Europe: an overview in the field of patents", The Handbook of European IP Management, 2012.

"Litigator Laëtitia Bénard heads both the IP practice in Paris and Allen & Overy’s life sciences group globally, gathering plaudits from the market for her finely tuned high-tech and pharmaceutical advice." IAM Patent 1000 - France 2019

Laëtitia Bénard - Ranked Gold in Litigation (IAM Patent 1000 - France 2019)

"Best in Patent" Euromoney LMG Europe Women in Business Law Awards 2019

"Intellectual Property Lawyer of the Year" Benchmark Litigation Europe 2019

"Laëtitia Bénard specialises in pharmaceutical patent litigation and is lauded as "an excellent lawyer for contentious matters." Another source enthuses: "She is famous for being a hard-working, excellent lawyer for patent matters," adding: "She is a determined and effective presence in court."" CHAMBERS & PARTNERS 2019 - France (Pharma/Life Science)

"Laëtitia Bénard is a market leader in IP and primarily acts on patent litigation cases for pharmaceutical companies. She is highly respected by clients and peers who highlight her client dedication and industry knowledge. She assisted Pfizer with a patent litigation case concerning the validity of a second medical use patent." CHAMBERS & PARTNERS 2019 - France (Intellectual Property)

"Leading Life sciences practitioner in France." - Euromoney Expert Guides: Best of the Best Global Awards 2019

"Litigation Star for IP Litigation in France " Benchmark Europe 2019

IP Star” and “Top 250 Woman in IP” Managing IP – Patents and Trademark 2018

“Laëtitia Bénard is described by clients as "very impressive" and "very knowledgeable about the pharmaceutical industry as a whole." She is further praised for her cross-border capabilities and her "pragmatic and result-oriented" nature.” – Chambers & Partners Europe 2018 - Pharma/Life Sciences– France

“Laëtitia Bénard is head of the firm's Paris IP practice. Clients say: "She is able to grasp complex issues and thinks about the big picture.” – Chambers & Partners Europe 2018 - Intellectual Property – France

"Peers shower Bénard with praise: ‘She’s an extremely hard worker with a tremendous reputation. Her importance in the IP scene is unquestionable.’.” - IAM PATENT 1000 – FRANCE, 2018

Pharmaceuticals powerhouse Bénard’s extremely impressive in court and has a strong understanding of procedural issues.” WTR 1000 – 2018

""Laëtitia is managing the team well
," says a market commentator. According to one client, Bénard is "highly skilled in litigation". Another client adds: "Laëtitia is the go-to lawyer for life sciences companies and her skills are second to none." MANAGING IP EUROPE, 2018

"Laëtitia Bénard heads the IP and litigation department: 'She is incredibly capable, knows her cases extremely well, anticipates questions before they arise and has a complete grasp of all aspects of IP litigation issues in France'.” IAM Patent 1000 – France, 2017

"Practice head Laëtitia Bénard is ‘very impressive and the must-use lawyer in the life sciences area’." Legal 500 – EMEA 2017 – Intellectual Property: Patents - France

"Laëtitia Bénard excels in all aspects of IP with a particular focus on the life sciences sector."  Chambers & Partners Europe 2017 - Intellectual Property – France

"Laëtitia Bénard is described as a 'very present and important' practitioner in the market. She has particular expertise in the life sciences sector." Who's Who Legal - France 2017

Professional qualifications

Admitted to the Bar, Paris, 2000

Academic qualifications

Post Graduate Degree, Industrial Property, University of Paris II Panthéon Assas, 1999

Post Graduate Degree, French Civil Law, University of Paris I Panthéon Sorbonne, 1998

Published work

‘Brexit’: time is of the essence for life sciences innovators – LSIPR (Life Sciences Intellectual Property Review) – June 2016

La juridiction unifiée du brevet (JUB) : un atout indéniable pour l'Europe, La Lettre des juristes d'affaires, July 2014

La juridiction unifiée du brevet (JUB) reçoit un soutien croissant des entreprises, Option Droit et Finance, July 2014 co-authored with David Por

France’s Biosimilar law may set trend inside the EU, Law 360, February 2014, co-authored with Eveline Van Keymeulen

L’Acte II de l’exception culturelle sur la scène du numérique, Les Echos, June 2013

"France" chapter, International Copyright Law book, Global Law & Business, May 2013, co-authored with Alexandre Rudoni and Olivia Klimis

Overview of Life Sciences law in France, Chambers Life Sciences Guide 2013, co-authored with Olivier Fréget, David Por and Olivia Klimis

Interim injunctions over patents, The French practice, Managing Intellectual Property, co-authored with Olivia Klimis

Choisir la stratégie juridique adéquate pour valoriser sa marque - Décryptage avec Laëtitia Bénard, Les Echos, December 2012

Comparative Advertising for generics in Germany and France after L’Oréal v Bellure, PTMG Law Lore & Practice, December 2012, co-authored with Oscar Benito, Rainer Kaase and Ralf Möller

Il faut sauver le projet de brevet unitaire européen, Option Droit & Affaires, September 2012, co-authored with Olivia Klimis

Preliminary injunctions in Europe: an overview in the field of patents, The Handbook of European IP Management, May 2012

Trade secrets protection: a comparative overview, The Handbook of European IP Management, May 2012, co-authored with  Benjamin Bai and Paul B. Keller

Why France is a good forum for preliminary injunctions in patent matters, Global Business Magazine, April 2012

Supplementatry protection certificates: CJEU provides welcome clarifications, Who's Who Legal, Life Sciences, April 2012, co-authored with Olivia Klimis

Trade secrets protection, Commerce International, April 2012

L'arrêt DHL/Chronopost de la CJUE du 12 avril 2011 : une injonction communautaire peut être obtenue dans les limites de l'atteinte aux fonctions de la marque, Revue Lamy Droit de l'immatériel, August/September 2011, co-authored with Alexandra Abello

Competition, Public Health, Innovation and Drugs, LGDJ, 2010, under the supervision of Marie-Anne Frison-Roche

Generic drugs and IP law, Lamy Droit de la Santé, 2002, 2004 and 2008

Question 202 of the AIPPI French group on "The impact of public health issues on exclusive patents rights", September 2008

The DADVSI law regarding television: three steps backward for right owners?, Legipresse, May 2007, co-authored with Alexandre Rudoni

Rights owners and users fail to agree on reform, Managing Intellectual Property, June 2006, co-authored with Alexandre Rudoni

How to prepare the businessmen in the biotechnology sector for the cession of their firm, Bio Futur, October 2005, co-authored with Alexandre Rudoni

Find a lawyer


  • Expertise


  • Search Clear


  • Add comment (optional)